Peminib (Pemigatinib) 13.5mg*14 | Ziska Bangladesh Generic | GLT

REQUEST A QUOTE

Tap "Request a Quote" to open WhatsApp — the product details are already filled in. Just add your quantity and destination country.

  • We reply within 24 hours with pricing, availability & COA
  • Serves individuals and institutions worldwide

Prefer email? [email protected] · +86 15234153837

Share
Product description

Generic Information: Peminib (Pemigatinib) 13.5mg — Bangladesh

Peminib is a Bangladesh-manufactured generic of pemigatinib produced by Ziska Pharmaceuticals Ltd., one of Bangladesh's established pharmaceutical companies. It is supplied at the 13.5 mg strength in 14-tablet packs — matching the originator's standard starting dose for cholangiocarcinoma. Peminib is Ziska's pemigatinib brand for FGFR2-altered bile duct cancer, offering patients in South Asia and beyond an affordable alternative to the high-priced originator.

Bangladesh has a well-developed generic pharmaceutical industry that supplies much of the developing world, and Ziska is a recognised name within it. Because Peminib comes in the 13.5 mg strength, it is used directly at the standard once-daily dose, making it a straightforward substitute for the originator without any dose conversion.

What Is Peminib Used For?

Peminib is prescribed for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma whose tumour carries an FGFR2 fusion or rearrangement. Cholangiocarcinoma is a rare and aggressive cancer of the bile ducts, often diagnosed late with limited options. Pemigatinib was the first targeted therapy approved for the FGFR2-altered subset, and Peminib delivers the same active ingredient at the standard dose.

How Does Peminib Work?

Pemigatinib, the active ingredient in Peminib, is a selective inhibitor of FGFR1, FGFR2 and FGFR3 kinases. When FGFR2 is fused or rearranged, the receptor stays switched on and drives uncontrolled cancer-cell growth. Peminib blocks this overactive pathway, slowing tumour progression through a targeted mechanism that spares many of the toxicities of conventional chemotherapy.

Indications

  • Previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement, confirmed by a validated test.
  • Adult patients who have progressed after at least one prior line of systemic therapy.

Dosage and Administration

The recommended dose is 13.5 mg once daily for 14 consecutive days, followed by 7 days off, in repeating 21-day cycles. Tablets are swallowed whole with water, with or without food. Regular monitoring of phosphate, renal function and eye health is advised, with ophthalmologic evaluation for any visual symptoms.

Side Effects

Common adverse reactions include hyperphosphatemia, diarrhoea, stomatitis, dry mouth, fatigue, nausea and alopecia. Serous retinal detachment is a serious risk that requires prompt reporting of visual changes. Dry eye, nail disorders and elevated liver enzymes are also observed, with most adverse events mild to moderate in severity.

Storage

Store Peminib below 25°C in the original package, away from moisture and direct light, out of the reach of children. Use before the printed expiry date.

Why Choose the GLT?

GLT sources Peminib through an audited Bangladesh-based supply chain and documents every batch, which matters for buyers who need a dependable, traceable generic alternative to the high-priced originator. Compared with the US list price of branded pemigatinib, Bangladesh and other regional generics typically cost a small fraction — often several times lower — making long-term FGFR-targeted therapy far more sustainable. We also provide clear purchase documentation and direct contact for ongoing support.

How to Order Peminib from GLT

To order Peminib 13.5 mg (14 tablets), contact GLT on WhatsApp at +86 15234153837 or email [email protected]. Tell us your quantity, shipping destination and whether you require a prescription or purchase order. We confirm batch details and lead time before dispatch.

FAQ

Is Peminib the same as Pemazyre? Peminib contains the same active ingredient (pemigatinib) at the standard 13.5 mg dose as Pemazyre; it is a generic manufactured in Bangladesh by Ziska Pharmaceuticals.

What strength is Peminib? Peminib is supplied at 13.5 mg, the standard once-daily pemigatinib dose.

Where can I order Peminib? GLT can supply Peminib to international buyers; reach us on WhatsApp or email for availability.

Related Oncology Products

SPINRAZA (Nusinersen) 12mg/5mL | Buy from China | SMA Therapy | GLT

Biogen's first-in-class antisense oligonucleotide for SMA, NMPA-approved and nationally reimbursed in China — buy from...

Barinib (Baricitinib) 2mg | Generic JAK1/JAK2 Inhibitor | Drug International Limited | GLT

Generic baricitinib (JAK1/JAK2 inhibitor) by Drug International Limited (Bangladesh) — an affordable alternative to Olumiant...

Mounjaro KwikPen (Tirzepatide) 10–60mg/2.4mL Multi-Dose | Eli Lilly USA | GLT

Mounjaro KwikPen — Eli Lilly single-patient multi-dose pen, six US strengths (10–60mg/2.4mL, 4 doses each)...

Tirzema (Tirzepatide) 2.5/5/7.5mg/0.5mL Single-Dose Pen | Incepta Bangladesh | GLT

Tirzema — Incepta Pharmaceuticals tirzepatide single-dose pen, three official strengths (2.5/5/7.5mg/0.5mL) for T2DM and weight...

XinKePing 欣可平 (Avatrombopag) 20mg*10 Tablets | Nanjing Hencer China | GLT

XinKePing — API-plus-tablet integrated avatrombopag from Nanjing Hencer Pharmaceutical (Jemcare group), China Mainland

Tixepa (Tirzepatide) 20mg/2mL & 30mg/2mL Multi-Dose Pen | Drug International | GLT

Tixepa — Drug International Limited (DIL) tirzepatide multi-dose pen, two official strengths (Tixepa-5 = 20mg/2mL,...

Orforglipron (LuciOrfor) 0.8–17.2mg Tablets | Laos Generic Oral GLP-1 | GLT

Lucius Pharmaceuticals (Laos) generic orforglipron, 6-dose titration for weight management

Palutini (Baricitinib) 4mg | Generic JAK1/JAK2 Inhibitor | Trans Continental Life Science & Pharmaceuticals (TLPH) | GLT

Generic baricitinib (JAK1/JAK2 inhibitor) by Trans Continental Life Science & Pharmaceuticals (TLPH) (Laos) — an...